Successfully designing and developing next-generation modalities, like antibody-oligonucleotide conjugates (AOCs) and bi/multi-specific antibodies, is a complex, multi-stage process. These innovative therapies require specialized expertise and the coordination of a diverse range of inputs and deliverables to overcome chemistry, technical, and regulatory hurdles. Despite this, there is an ever-increasing drive to get these transformative therapies to patients quicker. Consequently, the drug development sector is looking to balance speed with risk and to work with partners who can successfully deliver them on accelerated timelines to satisfy key stakeholders. This session will cover how to accelerate development timelines for next generation drugs such as AOCs and bispecific antibodies through a multifaceted approach that integrates innovative technologies and streamlined processes.